Literature DB >> 33271124

The case for an HIV cure and how to get there.

Mark Dybul1, Timothy Attoye2, Solange Baptiste3, Peter Cherutich4, François Dabis5, Steven G Deeks6, Carl Dieffenbach7, Brian Doehle2, Maureen M Goodenow8, Adam Jiang9, Dominic Kemps10, Sharon R Lewin11, Murray M Lumpkin2, Lauren Mathae12, Joseph M McCune2, Thumbi Ndung'u13, Moses Nsubuga14, Holly L Peay15, John Pottage16, Mitchell Warren17, Izukanji Sikazwe18.   

Abstract

In light of the increasing global burden of new HIV infections, growing financial requirements, and shifting funding landscape, the global health community must accelerate the development and delivery of an HIV cure to complement existing prevention modalities. An effective curative intervention could prevent new infections, overcome the limitations of antiretroviral treatment, combat stigma and discrimination, and provide a sustainable financial solution for pandemic control. We propose steps to plan for an HIV cure now, including defining a target product profile and establishing the HIV Cure Africa Acceleration Partnership (HCAAP), a multidisciplinary public-private partnership that will catalyse and promote HIV cure research through diverse stakeholder engagement. HCAAP will convene stakeholders, including people living with HIV, at an early stage to accelerate the design, social acceptability, and rapid adoption of HIV-cure products.
Copyright © 2021 The Author(s). Published by Elsevier Ltd. This is an Open Access article under the CC BY 4.0 license. Published by Elsevier Ltd.. All rights reserved.

Entities:  

Mesh:

Year:  2020        PMID: 33271124      PMCID: PMC7773626          DOI: 10.1016/S2352-3018(20)30232-0

Source DB:  PubMed          Journal:  Lancet HIV        ISSN: 2352-3018            Impact factor:   12.767


  17 in total

Review 1.  Research priorities for an HIV cure: International AIDS Society Global Scientific Strategy 2021.

Authors:  Steven G Deeks; Nancie Archin; Paula Cannon; Simon Collins; R Brad Jones; Marein A W P de Jong; Olivier Lambotte; Rosanne Lamplough; Thumbi Ndung'u; Jeremy Sugarman; Caroline T Tiemessen; Linos Vandekerckhove; Sharon R Lewin
Journal:  Nat Med       Date:  2021-12-01       Impact factor: 53.440

2.  Collaborative science to advance gene therapies in resource-limited parts of the world.

Authors:  Joseph M McCune; Susan C Stevenson; Brian P Doehle; Cameron C Trenor; Emily H Turner; Jonathan M Spector
Journal:  Mol Ther       Date:  2021-08-30       Impact factor: 11.454

3.  Pembrolizumab induces HIV latency reversal in people living with HIV and cancer on antiretroviral therapy.

Authors:  Thomas S Uldrick; Scott V Adams; Remi Fromentin; Michael Roche; Steven P Fling; Priscila H Gonçalves; Kathryn Lurain; Ramya Ramaswami; Chia-Ching Jackie Wang; Robert J Gorelick; Jorden L Welker; Liz O'Donoghue; Harleen Choudhary; Jeffrey D Lifson; Thomas A Rasmussen; Ajantha Rhodes; Carolin Tumpach; Robert Yarchoan; Frank Maldarelli; Martin A Cheever; Rafick Sékaly; Nicolas Chomont; Steven G Deeks; Sharon R Lewin
Journal:  Sci Transl Med       Date:  2022-01-26       Impact factor: 19.319

Review 4.  mRNA vaccines for infectious diseases: principles, delivery and clinical translation.

Authors:  Namit Chaudhary; Drew Weissman; Kathryn A Whitehead
Journal:  Nat Rev Drug Discov       Date:  2021-08-25       Impact factor: 112.288

Review 5.  The Potential of Nanomedicine to Unlock the Limitless Applications of mRNA.

Authors:  Laura Taina-González; María de la Fuente
Journal:  Pharmaceutics       Date:  2022-02-21       Impact factor: 6.321

6.  Biallelic, Selectable, Knock-in Targeting of CCR5 via CRISPR-Cas9 Mediated Homology Directed Repair Inhibits HIV-1 Replication.

Authors:  Stefan H Scheller; Yasmine Rashad; Fayez M Saleh; Kurtis A Willingham; Antonia Reilich; Dong Lin; Reza Izadpanah; Eckhard U Alt; Stephen E Braun
Journal:  Front Immunol       Date:  2022-03-21       Impact factor: 7.561

7.  Launching a multidisciplinary European collaboration towards a cure for HIV: The EU2Cure Consortium.

Authors:  C Rokx; H A B Prins; L Vandekerckhove; S J Fidler; J Frater; M Bracchi; O S Søgaard; M Tolstrop; T A Rasmussen; M Salgado; J Blanco; J Martinez-Picado; B Clotet; G Tambussi; A Groenendijk; A Verbon; C A B Boucher
Journal:  J Virus Erad       Date:  2021-05-23

Review 8.  In the Era of mRNA Vaccines, Is There Any Hope for HIV Functional Cure?

Authors:  Ignasi Esteban; Carmen Pastor-Quiñones; Lorena Usero; Montserrat Plana; Felipe García; Lorna Leal
Journal:  Viruses       Date:  2021-03-18       Impact factor: 5.048

9.  Diminished Peripheral CD29hi Cytotoxic CD4+ T Cells Are Associated With Deleterious Effects During SIV Infection.

Authors:  Omalla A Olwenyi; Samuel D Johnson; Kabita Pandey; Michellie Thurman; Arpan Acharya; Shilpa J Buch; Howard S Fox; Anthony T Podany; Courtney V Fletcher; Siddappa N Byrareddy
Journal:  Front Immunol       Date:  2021-10-13       Impact factor: 7.561

Review 10.  Can Broadly Neutralizing HIV-1 Antibodies Help Achieve an ART-Free Remission?

Authors:  Denise C Hsu; John W Mellors; Sandhya Vasan
Journal:  Front Immunol       Date:  2021-07-12       Impact factor: 7.561

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.